Nov. 29 (Bloomberg) -- A unit of German drugmaker Bayer AG sued India’s Lupin Ltd. in federal court alleging infringement of a U.S. patent for the birth-control pill Natazia.
Bayer Pharma AG, based in Berlin, contends Mumbai-based Lupin is planning to offer a generic copy of Natazia in the U.S. before the patent expires in 2026, according to a complaint filed yesterday in Wilmington, Delaware.
Bayer said it’s entitled to triple damages if Lupin markets the drug in violation of patent-protection laws.
Natazia tablets have been approved by the U.S. Food & Drug Administration for use as an oral contraceptive and to treat pathologically heavy menstruation in women, according to the complaint.
“We do not comment on ongoing litigations as a matter of policy,” Lupin’s communications manager, Shamsher Gorawara, said today by e-mail.
The case is Bayer Pharma AG v. Lupin Ltd., U.S. District Court, District of Delaware (Wilmington).
To see the patent, click: 8,071,577.
To contact the reporter on this story: Phil Milford at firstname.lastname@example.org.
To contact the editor responsible for this story: Michael Hytha at email@example.com.